Auropharma Rating
JPMORGAN ON AUROBINDO PH : 01.06.2021
* MAINTAIN OVERWEIGHT TARGET: 1,100
* Another good quarter for Aurobindo Pharma despite higher R&D; core business visibility + injectable optionality to support stock, JPMorgan says
* Another Good Quarter Despite Higher R&D
* Core Business Visibility + Injectable Optionality To Support Stock
* Merging Unit 16 W/Eugia A Step Closer To Exploring Value-unlocking Options
CLSA ON AUROBINDO PHARMA : 01.06.2021
* DOWNGRADE OUTPERFORM FROM BUY TARGET: 1,040 (PREVIOUS TARGET: 1.000)
* CLSA downgrades Aurobindo Pharma to OUTPERFORM from BUY, lowers FY23 EPS estimate by 2%
* Complex Product Pipeline Development Should Increase Medium-term R&D Spend
* Lower Our FY23 EPS Estimate By 2%
CS ON AUROBINDO PHARMA : 01.06.2021
* MAINTAIN OUTPERFORM TARGET: 1,080
* Credit Suisse likes Aurobindo Pharma's stock on account of large injectable biz, improving quality of filings. Here's more by the brokerage on the pharma co
* Good Injectable Play; Vaccine Opportunity Delayed
* Like The Stock On A/c Of Large Injectable Biz, Improving Quality Of Filings
* Like It On China opportunity & Bulk Drugs PLI scheme
GOLDMAN SACHS ON AUROBINDO PHARMA : 01.06.2021
* Maintain BUY, Target at Rs 1,140/share
* R&D ramps up to support complex pipeline
* Aurobindo reported a broadly in-line 4Q21
* Global injectable sales of US$111mn were up +2% QoQ
* Margins remained stable QoQ, despite the jump in R&D
* Trim our FY22-24 EPS estimates by up to 5% to factor in slower margin development
